Aprutumab

View Clinical trials for Aprutumab Get Aprutumab Patent Info for Free

NCI: An antibody against the fibroblast growth factor receptor type 2 (FGFR2), with potential antineoplastic activity. Upon administration, the anti-FGFR2 antibody BAY1179470 binds to and inhibits FGFR2, which may result in the inhibition of both FGFR2 phosphorylation and FGFR2-mediated signal transduction pathways. This results in the inhibition of cell proliferation and the induction of cell death of FGFR2-expressing tumor cells. FGFR2, upregulated in many tumor cell types, is a receptor tyrosine kinase, which is essential to tumor cellular proliferation, differentiation and survival.

Inn NameAprutumab
Lab CodesBAY-1179470
Chemical NameImmunoglobulin G1-lambda1, anti-[Homo sapiens FGFR2 (fibroblast growth factor receptor 2, keratinocyte growth factor receptor, KGFR, CD332)], Homo sapiens monoclonal antibody; gamma1 heavy chain (1-451) [Homo sapiens VH (IGHV3- 23*01 (98.00%) -(IGHD) -IGHJ5*02) [8.8.15](1-122) - IGHG1*01, Gm17,1 (CH1 (123-220), hinge (221-235), CH2 (236-345), CH3 (346-450),CHS K>del (451)) (123-451)], (225-215')-disulfide with lambda1 light chain (1'-216') [Homo sapiens V-LAMBDA (IGLV1-47*01 (90.70%) - IGLJ3*02) [8.3.11] (1'-110') -IGLC2*01 (111'-216')]; dimer (231-231'':234-234'')-bisdisulfide
SequenceHeavy chain
EVQLLESGGG LVQPGGSLRL SCAASGFTFS SYAMSWVRQA PGKGLEWVSA 50
ISGSGTSTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARVR 100
YNWNHGDWFD PWGQGTLVTV SSASTKGPSV FPLAPSSKST SGGTAALGCL 150
VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ SSGLYSLSSV VTVPSSSLGT 200
QTYICNVNHK PSNTKVDKKV EPKSCDKTHT CPPCPAPELL GGPSVFLFPP 250
KPKDTLMISR TPEVTCVVVD VSHEDPEVKF NWYVDGVEVH NAKTKPREEQ 300
YNSTYRVVSV LTVLHQDWLN GKEYKCKVSN KALPAPIEKT ISKAKGQPRE 350
PQVYTLPPSR DELTKNQVSL TCLVKGFYPS DIAVEWESNG QPENNYKTTP 400
PVLDSDGSFF LYSKLTVDKS RWQQGNVFSC SVMHEALHNH YTQKSLSLSP 450
G 451

Light chain
QSVLTQPPSA SGTPGQRVTI SCSGSSSNIG NNYVSWYQQL PGTAPKLLIY 50
ENYNRPAGVP DRFSGSKSGT SASLAISGLR SEDEADYYCS SWDDSLNYWV 100
FGGGTKLTVL GQPKAAPSVT LFPPSSEELQ ANKATLVCLI SDFYPGAVTV 150
AWKADSSPVK AGVETTTPSK QSNNKYAASS YLSLTPEQWK SHRSYSCQVT 200
HEGSTVEKTV APTECS 216

Disulfide bridges location
Intra-H (C23-C104) 22-96 149-205 266-326 372-430
22''-96'' 149''-205'' 266''-326'' 372''-430''
Intra-L (C23-C104) 22'-89' 138'-197'
22'''-89''' 138'''-197'''
Inter-H-L (h 5-CL 126) 225-215' 225''-215'''
Inter-H-H (h 11, h 14) 231-231' 234-234''

N-glycosylation sites
H CH2 N84.4:
302, 302''
Fucosylated complex bi-antennary CHO-type glycans
Chemical StructureAprutumab.png
Cas Registry Number1634620-63-5
New Molecular EntityYes
OriginatorBayer
Mechanism Of ActionType-2 fibroblast growth factor receptor antagonist, Keratinocyte growth factor receptor antagonist
Who Atc CodesL01 (Antineoplastic Agents)
Ephmra CodesL1 (Antineoplastics)
IndicationNeoplasms

Free counters!